SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Yul Brynner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientYul Brynner
Date of birth1920-07-11
IdentifiersMRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572
Document date1983-09-22
AuthorSimon Achterberg, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Tissue sequencing result and start of first-line pembrolizumab. [S]

History of Present Illness

Mr. Brynner returns one week later. The tissue sequencing report arrived yesterday: KRAS G12V and TP53 mutations, with no EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14, RET, NTRK, HER2, or NRG1 alteration, in agreement with the plasma result. With the thoracic oncologist he chose pembrolizumab alone, given every 3 weeks, rather than with chemotherapy, because it is a preferred first-line option at his PD-L1 level and spares him the fatigue and nausea of chemotherapy while he works toward the stage. His first infusion is this afternoon. The dental examination four days ago found no problems. He is unchanged: weak voice, a little morning cough, no pain, and steady weight. The visit ran long with treatment teaching, and the symptom questionnaire was not completed. [S]

ElementDetail
Tissue sequencingKRAS G12V and TP53; no actionable alteration
Treatment decisionPembrolizumab 200 mg every 3 weeks, first dose today
Dental statusExamination four days ago; no work needed
SymptomsUnchanged; no pain
TobaccoNo tobacco

Review of Systems

SystemResultFinding
RespiratoryPositiveMorning dry cough; no hemoptysis
GastrointestinalNegativeBowels regular; no abdominal pain
EndocrineNegativeNo heat or cold intolerance, thirst, or dizziness
IntegumentaryNegativeNo rash or itching

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Pembrolizumab 200 mg intravenous infusion over 30 minutes every 3 weeksEvery 3 weeks in the oncology infusion unit, after the immune-related adverse event laboratory panelIntravenous route1983-09-22activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1983-09-22Body height178cmS
1983-09-22Body weight71.8kgS
1983-09-22Body mass index (BMI) [Ratio]22.7kg/m2S
1983-09-22Systolic blood pressure126mm[Hg]S
1983-09-22Diastolic blood pressure78mm[Hg]S
1983-09-22Heart rate78/minS
1983-09-22Respiratory rate16/minS
1983-09-22Body temperature36.6CelS
1983-09-22Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1983-09-22Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4 mIU/LNormalS
1983-09-22Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
1983-09-22Cortisol [Mass/volume] in Serum or Plasma14.2ug/dLMorning (8 a.m.) reference intervalNormalS
1983-09-22Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma26U/L7-55 U/LNormalS
1983-09-22Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L8-48 U/LNormalS
1983-09-22Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma101U/L40-129 U/LNormalS
1983-09-22Bilirubin.total [Mass/volume] in Serum or Plasma0.6mg/dL0.1-1.2 mg/dLNormalS
1983-09-22Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.7-1.3 mg/dLNormalS
1983-09-22Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1978)/1.73 sq M92mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1983-09-22Glucose [Mass/volume] in Serum or Plasma94mg/dL70-99 mg/dLNormalS
1983-09-22Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
1983-09-22Hemoglobin [Mass/volume] in Blood13.6g/dL13.5-17.5 g/dLNormalS
1983-09-22Leukocytes [#/volume] in Blood by Automated count7.610*3/uL4-11 10*3/uLNormalS
1983-09-22Platelets [#/volume] in Blood by Automated count28410*3/uL150-400 10*3/uLNormalS

Physical Exam

Vital signs recorded on 1983-09-22; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 71.8 kg
VoiceBreathy, low-volume voice
LungsSlightly reduced breath sounds at the left apex
SkinNo rash

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notesactiveconfirmed C34.12S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.
Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.
Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary windowactiveconfirmed J38.01S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.
Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosisactiveconfirmed R91.8S — Synthetic presenting imaging finding, recorded before the tissue diagnosis.
Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco sinceactiveconfirmed Z87.891S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBroad molecular profiling (tissue and plasma)At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progressionCompleted todayTissue sequencing: KRAS G12V and TP53; no actionable alteration; concordant with plasma
LaboratoryImmune-related adverse event laboratory panelBefore each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicatedCompleted todayBaseline: TSH 2.1, free T4 1.2, morning cortisol 14.2, ALT 26, AST 23, alkaline phosphatase 101, bilirubin 0.6, glucose 94, all normal
LaboratoryBlood count, kidney function, and calcium before systemic therapyBefore each cycleCompleted todayHemoglobin 13.6, white cells 7.6, platelets 284, creatinine 0.9 (eGFR 92), calcium 9.5
ImagingResponse assessment imagingEvery 6 to 12 weeks on active systemic therapyDueFirst response CT about nine weeks after starting
ExaminationDyspnea and cough assessmentEvery visitCompleted todayMorning dry cough; unchanged
Self-managementSmoking status and cessation supportEvery visitCompleted todayFormer smoker; no tobacco
SurveyDistress and symptom screening (NCCN Distress Thermometer, ESAS)Every visit; at minimum at key transitionsDeferredNot done today, at the start of treatment, a key transition: the visit ran long with treatment teaching. Deviation from the every-visit and key-transition screen. No harm resulted: the palliative care team assessed his symptoms and distress in full a week later, and the next scores were lower. Corrective action: the ESAS and distress thermometer are now completed on a tablet at check-in, before the clinician sees him
SurveyCancer-related fatigue screeningEvery visitCompleted todayTired by evening, unchanged; no daytime naps
ExaminationWeight and dietary reviewEach follow-upCompleted today71.8 kg, stable
Medication safetyDental evaluation before a bone-modifying agentBaseline, then periodically on zoledronic acid or denosumabCompleted todayExamination four days ago: no active disease, no extractions needed
ReferralEarly integrated palliative careWithin eight weeks of diagnosis of advanced cancerReferredFirst visit next week
Self-managementVoice and work supportAs neededReferredInjection medialization in two weeks; voice therapy started
Medication safetyChemotherapy-induced peripheral neuropathyEvery visit during and after platinum or taxaneNot indicatedPembrolizumab alone; no platinum or taxane

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026)

Follow-up: First pembrolizumab infusion this afternoon. Palliative care next week. Voice injection in two weeks. Cycle 2 in three weeks with the laboratory panel and the first zoledronic acid dose. Call the oncology line for any warning symptom. Next scheduled visit 1983-10-13: cycle 2 review: immune-related adverse event monitoring, symptoms, and return to work. [S]